European Organization for Quality

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Retrieved on: 
Sunday, October 15, 2023
Science, Other Science, Radiology, Research, Oncology, Health, Medical Devices, Clinical Trials, Congress, Neoplasm, Treatment, NSCLC, GBM, European Organization for Quality, Central nervous system, PROC, Cognitive Function Scanner, Patient satisfaction, CEST, ESMO, Ovarian cancer, Quality of life (healthcare), Clinical trial, European Society for Medical Oncology, Glioblastoma, SLR, Patient, Pharmaceutical industry, Medical imaging, DACH

Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid.
  • The new analysis of data from LUNAR utilized The European Organization for Research and Treatment of Cancer Quality of Life questionnaire-C30.
  • Most said they would recommend TTFields therapy to a friend or acquaintance with GBM.
  • Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): a systematic literature review (SLR).

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, European, ALS, EudraCT, Food, European Directive on Traditional Herbal Medicinal Products, CHMP, Eupales, Frustration, European Organization for Quality, Committee for Medicinal Products for Human Use, Health Canada, European Commission, Safety, European Medicines Agency, Survival, EMA, Marketing Authorisation Application, FDA, AMX0035, Marketing, Clinical trial, Committee, Patient, Medication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Civil service commission, MAA, Pharmaceutical industry, Amylyx Pharmaceuticals, PHOENIX, EU

The decision follows the conclusion of the CHMP’s formal re-examination procedure of an initial negative opinion adopted in June 2023.

Key Points: 
  • The decision follows the conclusion of the CHMP’s formal re-examination procedure of an initial negative opinion adopted in June 2023.
  • Since the medication’s approval with conditions in Canada and full approval in the U.S., thousands of people have been prescribed AMX0035 in North America.
  • PHOENIX is a 48-week, randomized placebo-controlled global Phase 3 clinical trial further evaluating the safety and efficacy of AMX0035 for the treatment of ALS.
  • The CHMP opinion will be forwarded to the European Commission, who will adopt the final decision on this application.

CamundaCon 2023 Spotlights Process Orchestration Innovation and Practical Use Cases to Scaling Automation Value

Retrieved on: 
Tuesday, August 22, 2023
Technology, Insurance, Finance, Banking, Telecommunications, Professional Services, Business, Software, Electronic Design Automation, Data Management, EY, Municipality, Capital One, Organization, Cisco, European Organization for Quality, Capital, NatWest, Entrepreneurship, Infosys, Automation, CERN, Mobile phone, Management, HCLTech

Process orchestration leader Camunda announces speakers and sponsors for CamundaCon 2023 , taking place September 27-28 in New York, N.Y. and virtually live-streaming throughout the world.

Key Points: 
  • Process orchestration leader Camunda announces speakers and sponsors for CamundaCon 2023 , taking place September 27-28 in New York, N.Y. and virtually live-streaming throughout the world.
  • More than 40 speakers will present on scaling the value of process orchestration, and gaining higher automation maturity by leveraging the latest innovations.
  • “CamundaCon is an opportunity for all involved in automation to gather and share experiences, best practices, and insights about how process orchestration delivers value for their organizations,” said Jakob Freund, CEO at Camunda.
  • “Organizations will congregate in New York City to share their success across all industries — from sparking innovation to maturing and accelerating their organizations’ process orchestration journeys.

Ivalua and CKS Consulting Announce Successful Implementation of Requests-for-Quotations Solution at CERN

Retrieved on: 
Thursday, July 6, 2023
CERN, Request, European Organization for Quality, CKS, RFQ, Spot, Automotive industry, Sales

As a partner and reseller of Ivalua, CKS Consulting was the single point of contact for the CERN project team, handling both the platform's configuration and its integration within a demanding IT landscape, and supporting the change management activities.

Key Points: 
  • As a partner and reseller of Ivalua, CKS Consulting was the single point of contact for the CERN project team, handling both the platform's configuration and its integration within a demanding IT landscape, and supporting the change management activities.
  • "CKS and Ivalua provided us with an easy-to-use and efficient solution that allows us to simplify processes for our users," said Vlad Armeanu, Product Manager, Procurement and Supply Chain business software solutions at CERN.
  • "We look forward to opening a new chapter of procurement digitalization with Ivalua and CKS Consulting."
  • "CKS is extremely proud to partner with Ivalua to bring value to CERN, a globally recognized, flagship scientific institution.

IBM to Build its First European Quantum Data Center to Serve Expanding Ecosystem

Retrieved on: 
Tuesday, June 6, 2023
Workforce, CERN, PSNC, IBM, Partnership, IBM Quantum Experience, Software, Deutsche Telekom, Research, Government, Organization, IBM Research, Bundeswehr University Munich, T-Systems, European Organization for Quality, China Earthquake Networks Center, Ecosystem, Fraunhofer, IBM Fellow, Quantum, NYSE, DESY, Fraunhofer Society, Microscope, Targobank, EU

ARMONK, N.Y. and EHNINGEN, Germany, June 6, 2023 /PRNewswire/ -- Today, IBM (NYSE: IBM) announced plans to open its first Europe-based quantum data center to facilitate access to cutting-edge quantum computing for companies, research institutions and government agencies.

Key Points: 
  • The data center will be located at IBM's facility in Ehningen, Germany, and will serve as IBM Quantum's European cloud region.
  • The data center is being designed to help clients continue to manage their European data regulation requirements, including processing all job data within EU borders.
  • The facility will be IBM's second quantum data center and quantum cloud region, after Poughkeepsie, New York.
  • "We are happy and proud to support the IBM Quantum team's decision to set up their European quantum data center in Ehningen, Germany," said Dr. Raoul Klingner, Director Research, Fraunhofer-Gesellschaft.

IBM to Build its First European Quantum Data Center to Serve Expanding Ecosystem

Retrieved on: 
Tuesday, June 6, 2023
Workforce, CERN, PSNC, IBM, Partnership, IBM Quantum Experience, Software, Deutsche Telekom, Research, Government, Organization, IBM Research, Bundeswehr University Munich, T-Systems, European Organization for Quality, China Earthquake Networks Center, Ecosystem, Fraunhofer, IBM Fellow, Quantum, NYSE, DESY, Fraunhofer Society, Microscope, Targobank, EU

ARMONK, N.Y. and EHNINGEN, Germany, June 6, 2023 /PRNewswire/ -- Today, IBM (NYSE: IBM) announced plans to open its first Europe-based quantum data center to facilitate access to cutting-edge quantum computing for companies, research institutions and government agencies.

Key Points: 
  • The data center will be located at IBM's facility in Ehningen, Germany, and will serve as IBM Quantum's European cloud region.
  • The data center is being designed to help clients continue to manage their European data regulation requirements, including processing all job data within EU borders.
  • The facility will be IBM's second quantum data center and quantum cloud region, after Poughkeepsie, New York.
  • "We are happy and proud to support the IBM Quantum team's decision to set up their European quantum data center in Ehningen, Germany," said Dr. Raoul Klingner, Director Research, Fraunhofer-Gesellschaft.

Edison Investment Research Limited: Creotech Instruments (CRI): Initiation – A leader in EEC spacetech and quantum

Retrieved on: 
Tuesday, April 18, 2023
CERN, Warsaw Stock Exchange, Research, European Organization for Quality, Telecommunications, Communications satellite

Creotech Instruments is Poland’s leading space tech company, founded in 2012 by alumni of CERN, the European Organization for Nuclear Research.

Key Points: 
  • Creotech Instruments is Poland’s leading space tech company, founded in 2012 by alumni of CERN, the European Organization for Nuclear Research.
  • In July 2022, the company’s shares transferred to the main market of the Warsaw Stock Exchange’s following a PLN40m (gross) capital raise.
  • Creotech is one of only a few companies worldwide that is developing controls for quantum computers and quantum telecommunications.
  • Click here to view the full report or here to sign up to receive research as it is published.

Global Rare Disease Therapeutics Market Report 2023: Players Include AbbVie, Novo Nordisk, Sanofi, Bayer, Amgen and Eisai - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 5, 2023
Biotechnology, Pharmaceutical, Health, Orphan Drug Act of 1983, CDER, COVID-19, Therapy, Disease, NORD, Bone marrow, DSM-IV codes, Pharmacy, Loncastuximab tesirine, Infection, National Organization for Rare Disorders, USD, Competition, Market, Malignancy, Administration, EURORDIS, Rare, Patient, Laboratory, European Organization for Quality, European, Center for Drug Evaluation and Research, Route of administration, Knowledge, Pharmaceutical Research and Manufacturers of America, Global Genes, D, Pharmaceutical industry, Research, Mobocertinib

The global rare disease therapeutics market is projected to undergo a vigorous expansion in the coming years.

Key Points: 
  • The global rare disease therapeutics market is projected to undergo a vigorous expansion in the coming years.
  • The market for treating rare diseases will expand as the number of rare diseases rises.
  • Therefore, continued market expansion prospects will arise from research into unmet rare disease treatments in the future.
  • According to clinicaltrials.gov, there are around 2,615 studies related to rare disease therapeutics which are in different phases of development across different parts of the globe.

Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)

Retrieved on: 
Wednesday, January 11, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Congress, Radiation, Kidney, Prostate, Brain, OTC Markets Group, University, Neoplasm, PRP, Quality of life, POP1, Breast, Skin, MD, PAMM, Tumor microenvironment, Bachelor of Medicine, Bachelor of Surgery, Lung, Treatment, Trypsinogen, Chymotrypsinogen, Partnership, MB, PPCB, Growth, Patient, Pharmacology, TME, EORTC, Liver, Recurrence, III, European Organization for Quality, Pharmaceutical industry, Cancer, Research

Mrs. Toledo Cutillas commented that results and discussion on the novel approach was well received at the Congress in Florence, Italy.

Key Points: 
  • Mrs. Toledo Cutillas commented that results and discussion on the novel approach was well received at the Congress in Florence, Italy.
  • The EORTC research network consists of over 5,500 collaborators from all disciplines involved in cancer treatment and research in more than 930 institutions in 27 countries.
  • Its research spans the entire spectrum from translational and pre-clinical research to large, prospective, multi-center, phase III clinical trials that evaluate new cancer therapies.
  • Propanc is currently undertaking two joint research and collaboration projects with the Universities of Jáen and Granada.

Aviation and Defense Cyber Security Global Market Report 2022: Market to Surpass $100 Billion in 2026 - Long-term Forecasts to 2031 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Security, Defense, Technology, Aerospace, Manufacturing, Other Defense, Theft, Anomaly, European Organization for Quality, Defense, Aviation, Growth, Research report, Cyberattack, Internet, Airport, Safety, Weapon

The "Aviation and Defense Cyber Security Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aviation and Defense Cyber Security Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The aviation and defense cyber security market research report is one of a series of new reports that provides aviation and defense cyber security market statistics, including aviation and defense cyber security industry global market size, regional shares, competitors with an aviation and defense cyber security market share, detailed aviation and defense cyber security market segments, market trends and opportunities, and any further data you may need to thrive in the aviation and defense cyber security industry.
  • Therefore, the rising cyber-attacks in the aircraft industry are driving the demand for the aviation and defense cyber security market.
  • The countries covered in the aviation and defense cyber security market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.